Veloxis Pharmaceuticals A/S – annulment of warrants and registration of new Articles of Association pursuant thereto


Company Announcement no. 14/2013
Hørsholm, Denmark, May 30, 2013

Today, the Board of Directors of Veloxis Pharmaceuticals A/S (the "Company") has decided to annul 18,728,293 warrants, which the Company has repurchased from a number of employees.

The amendment of the Articles of Association pursuant to the annulment of warrants has today been registered with the Danish Business Authority. The new Articles of Association of Veloxis Pharmaceuticals A/S are attached.

For more information, please contact:

Veloxis Pharmaceuticals A/S

Bill Polvino                                              Johnny Stilou
President & CEO                                     EVP, Chief Financial Officer
Mobile: +1 917 647 9107                      Mobile: +45 21 227 227
Email: wjp@veloxis.com                         Email: jst@veloxis.com

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com. 


Attachments

300513 Articles of Association.pdf 300513 Veloxis Announces Annulment of Warrants.pdf